Head to head
Retatrutide against Mazdutide
Both add glucagon receptor activity to GLP-1. Mazdutide was approved in China in 2025 and is not FDA-approved; retatrutide is not approved anywhere. Approval status in one country is the clearest difference between them at this point, not a measured difference in effect.
Column A
RetatrutideRetatrutide (triple GLP-1/GIP/glucagon agonist)
An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials.
Column B
MazdutideMazdutide (GLP-1 / glucagon dual agonist)
A GLP-1 and glucagon receptor dual agonist approved in China in 2025 for obesity and type 2 diabetes, the first of its class approved anywhere, and not approved by the FDA.
Side by side, on the facts we can check
| Attribute | Retatrutide | Mazdutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026 | Approved in China (2025) for obesity and type 2 diabetes; investigational elsewhere |
| Half-life | ~6 days | ~5-7 days |
| Molecular weight | ~4,731 Da | ~4,800 Da |
| Mechanism | Agonizes GLP-1, GIP, and glucagon receptors. The added glucagon activity increases energy expenditure and hepatic fat oxidation, complementing the appetite and insulin effects of the incretin receptors. | Agonizes GLP-1 and glucagon receptors to reduce appetite and improve glucose control while increasing energy expenditure. |
| Human studies cited | 3 | 2 |
| Legal status, US | Investigational, not approved for any indication | Not approved |
Frequently asked questions
What is the difference between Retatrutide and Mazdutide?
Retatrutide: An investigational once-weekly triple receptor agonist producing the largest pharmacological weight loss reported to date in trials. Mazdutide: A GLP-1 and glucagon receptor dual agonist approved in China in 2025 for obesity and type 2 diabetes, the first of its class approved anywhere, and not approved by the FDA.
Which has stronger research evidence, Retatrutide or Mazdutide?
This database does not grade compounds. It counts what was run in people: 3 of the 4 studies cited on the Retatrutide profile were human work, against 2 of 3 for Mazdutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Retatrutide and Mazdutide FDA-approved?
Retatrutide: Investigational, not FDA-approved; Phase 3 TRIUMPH-1 reported May 2026; submission expected late 2026. Mazdutide: Approved in China (2025) for obesity and type 2 diabetes; investigational elsewhere.
Related posts
Blog articles that cover Retatrutide or Mazdutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.